Pyrimidines

• 

  Subject Areas on Research

  • 3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates. 
  • A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome. 
  • A Small Molecule Pyrazolo[3,4-d]Pyrimidinone Inhibitor of Zipper-Interacting Protein Kinase Suppresses Calcium Sensitization of Vascular Smooth Muscle. 
  • A case of scurvy associated with nilotinib. 
  • A mutational analysis of the polypyrimidine tract of introns. Effects of sequence differences in pyrimidine tracts on splicing. 
  • A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. 
  • A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. 
  • A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. 
  • A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. 
  • A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. 
  • A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. 
  • A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. 
  • A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). 
  • A phase II study of piritrexim in patients with advanced squamous head and neck cancer. 
  • A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group. 
  • A study of the binding of thiamine diphosphate and thiochrome diphosphate to the pyruvate dehydrogenase multienzyme complex. 
  • A validated LC method for imatinib mesylate. 
  • Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages. 
  • Abl family kinases regulate endothelial barrier function in vitro and in mice. 
  • Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. 
  • Acute chiasmal abscess resulting from perineural extension of invasive sino-orbital aspergillosis in an immunocompetent patient. 
  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. 
  • Allelic exclusion of the TCR alpha-chain is an active process requiring TCR-mediated signaling and c-Cbl. 
  • An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo. 
  • Anterior rectal wall gastrointestinal stromal tumor presenting clinically as prostatic mass. 
  • Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. 
  • Antifungal agents in children. 
  • Antifungal resistance: the clinical front. 
  • Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. 
  • Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. 
  • Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. 
  • Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia. 
  • BMP signaling and cellular dynamics during regeneration of airway epithelium from basal progenitors. 
  • Base stacking and molecular polarizability: effect of a methyl group in the 5-position of pyrimidines. 
  • Basic matrices for the matrix-assisted laser desorption/ionization mass spectrometry of proteins and oligonucleotides. 
  • Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. 
  • Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. 
  • Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. 
  • Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. 
  • Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. 
  • Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. 
  • Caspofungin for the treatment of azole resistant candidemia in a premature infant. 
  • Cellular fatty acid synthase is required for late stages of HIV-1 replication. 
  • Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. 
  • Characterization of the usage of the serine metabolic network in human cancer. 
  • Chronic myelogenous leukemia. 
  • Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. 
  • Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. 
  • Clinical and in vitro studies of imatinib in advanced carcinoid tumors. 
  • Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. 
  • Coenzyme Q10 and statins in heart failure: the dog that didn't bark. 
  • Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. 
  • Combining targeted agents with modern radiotherapy in soft tissue sarcomas. 
  • Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. 
  • Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. 
  • Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. 
  • Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. 
  • Compartmental transport model of microbicide delivery by an intravaginal ring. 
  • Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. 
  • Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. 
  • Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. 
  • Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. 
  • Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. 
  • Crystal structures of Toxoplasma gondii uracil phosphoribosyltransferase reveal the atomic basis of pyrimidine discrimination and prodrug binding. 
  • Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. 
  • Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression. 
  • Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. 
  • Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. 
  • Defective T cell development and function in the absence of Abelson kinases. 
  • Delayed recalcitrant fungal endophthalmitis secondary to Curvularia. 
  • Determinants of Photolyase's DNA Repair Mechanism in Mesophiles and Extremophiles. 
  • Developmental sensitivity of hippocampal interneurons to ethanol: involvement of the hyperpolarization-activated current, Ih. 
  • Differential sensitivity of hippocampal interneurons to ethanol in adolescent and adult rats. 
  • Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. 
  • Dissecting the differences between the alpha and beta anomers of the oxidative DNA lesion FaPydG. 
  • Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. 
  • Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. 
  • E2A and IRF-4/Pip promote chromatin modification and transcription of the immunoglobulin kappa locus in pre-B cells. 
  • Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. 
  • Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. 
  • Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. 
  • Effect of famoxadone on photoinduced electron transfer between the iron-sulfur center and cytochrome c1 in the cytochrome bc1 complex. 
  • Effect of pazopanib on tumor microenvironment and liposome delivery. 
  • Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. 
  • Emerging treatments for ulcerative colitis: a systematic review. 
  • Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells. 
  • Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. 
  • Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. 
  • Evidence for brain glial activation in chronic pain patients. 
  • Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. 
  • FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. 
  • Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. 
  • Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients. 
  • Fatal hepatic necrosis following imatinib mesylate therapy. 
  • Fluorescence energy transfer between the thiamine diphosphate and flavine adenine dinucleotide binding sites on the pyruvate dehydrogenase multienzyme complex. 
  • Fluorescent derivatives of the pyruvate dehydrogenase component of the Escherichia coli pyruvate dehydrogenase complex. 
  • Fluorescent-Linked Enzyme Chemoproteomic Strategy (FLECS) for Identifying HSP70 Inhibitors. 
  • Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. 
  • Focusing on inflammation in the treatment of atherosclerosis. 
  • Free radicals formed by exposure of pyrimidine solids to sodium atoms: an electron spin resonance study. 
  • Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt). 
  • Gastrointestinal stromal tumors, version 2.2014. 
  • Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. 
  • Gleevec, an Abl family inhibitor, produces a profound change in cell shape and migration. 
  • HASF (C3orf58) is a novel ligand of the insulin-like growth factor 1 receptor. 
  • Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer. 
  • IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation. 
  • Ibrutinib: a new targeted therapy for hematologic cancers. 
  • Identification and biochemical studies on novel non-nucleoside inhibitors of the enzyme adenosine kinase. 
  • Identification and purification of a 62,000-dalton protein that binds specifically to the polypyrimidine tract of introns. 
  • Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. 
  • Improved outcome in central nervous system aspergillosis, using voriconazole treatment. 
  • Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. 
  • In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 
  • Increasing occurrences and functional roles for high energy purine-pyrimidine base-pairs in nucleic acids. 
  • Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. 
  • Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. 
  • Inhibiting glycogen synthase kinase-3 mitigates the hematopoietic acute radiation syndrome in mice. 
  • Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. 
  • Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. 
  • Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. 
  • Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. 
  • Initial testing of dasatinib by the pediatric preclinical testing program. 
  • Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). 
  • Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. 
  • Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. 
  • Insight into the CSA tensors of nucleobase carbons in RNA polynucleotides from solution measurements of residual CSA: towards new long-range orientational constraints. 
  • Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. 
  • International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. 
  • Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. 
  • Kidney cancer, version 3.2015. 
  • Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. 
  • Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. 
  • Measuring carotid artery intima-media thickness: simplicity versus complexity? 
  • Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. 
  • Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. 
  • Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. 
  • Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. 
  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. 
  • NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. 
  • Neurofibromatosis type 2. 
  • New treatments for methicillin-resistant Staphylococcus aureus. 
  • Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. 
  • Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. 
  • On the specificity of creatine kinase. New glycocyamines and glycocyamine analogs related to creatine. 
  • Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. 
  • Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. 
  • Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS. 
  • PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. 
  • Paliperidone: a review of clinical trial data and clinical implications. 
  • Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. 
  • Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. 
  • Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. 
  • Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. 
  • Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells. 
  • Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. 
  • Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. 
  • Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. 
  • Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. 
  • Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. 
  • Phase I study of pazopanib plus TH-302 in advanced solid tumors. 
  • Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. 
  • Phase I trial of pazopanib in patients with advanced cancer. 
  • Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. 
  • Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. 
  • Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. 
  • Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. 
  • Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. 
  • Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. 
  • Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome. 
  • Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. 
  • Platelet-derived growth factor receptors: a therapeutic target in solid tumors. 
  • Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis. 
  • Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction. 
  • Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. 
  • Probing sequence-specific DNA flexibility in a-tracts and pyrimidine-purine steps by nuclear magnetic resonance (13)C relaxation and molecular dynamics simulations. 
  • Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. 
  • Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. 
  • Purine nucleoside phosphorylase deficiency. 
  • Radiation-induced lung injury is mitigated by blockade of gastrin-releasing peptide. 
  • Randomized Trial to Evaluate Tandospirone in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GATE Study. 
  • Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. 
  • Requirement for Abl kinases in T cell receptor signaling. 
  • Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy. 
  • Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. 
  • Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition. 
  • Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor. 
  • Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. 
  • Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. 
  • SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma. 
  • Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. 
  • Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. 
  • Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta. 
  • Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. 
  • Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. 
  • Solution structure of a pyrimidine-purine-pyrimidine triplex containing the sequence-specific intercalating non-natural base D3. 
  • Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. 
  • Structures of mismatch replication errors observed in a DNA polymerase. 
  • Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. 
  • Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. 
  • Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists. 
  • Synthesis and pharmacological evaluation of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for a novel receptor with sigma-like neuromodulatory activity. 
  • Synthesis of 5-(1-propynyl)-2'-deoxyuridine 5'-(alpha-P-borano)triphosphate and kinetic characterization as a substrate for mmlv reverse transcriptase. 
  • Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase. 
  • Targeting One Carbon Metabolism with an Antimetabolite Disrupts Pyrimidine Homeostasis and Induces Nucleotide Overflow. 
  • The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. 
  • The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. 
  • The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-A potential therapeutic target. 
  • The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. 
  • The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia. 
  • The role of the de novo pyrimidine biosynthetic pathway in Cryptococcus neoformans high temperature growth and virulence. 
  • The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. 
  • Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. 
  • Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. 
  • Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. 
  • Trypanosoma brucei gambiense: growth in vitro of bloodstream forms inhibited by dichlorodiammineplatinum (II) compounds and hypolipidemic drugs. 
  • Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. 
  • Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. 
  • Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. 
  • Use of newer antifungal therapies in clinical practice: what do the data tell us? 
  • Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). 
  • Vascular smooth muscle cell migration induced by domains of thrombospondin-1 is differentially regulated. 
  • Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. 
  • Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. 
  • Voriconazole treatment for less-common, emerging, or refractory fungal infections. 
  • When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia. 
  • X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase. 
  • ZIP kinase, a key regulator of myosin protein phosphatase 1. 
  • [Clinical study of Daritran]. 
  • alpha-Crystallin localizes to the leading edges of migrating lens epithelial cells. 
  • β-Cell Inactivation of Gpr119 Unmasks Incretin Dependence of GPR119-Mediated Glucoregulation. 
  • β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Professor of Medical Oncology, Medicine, Medical Oncology
  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Katz, David F., Nello L. Teer, Jr. Professor of Biomedical Engineering, in the Edmund T. Pratt, Jr. School of Engineering, Biomedical Engineering
  • McCall, Shannon Jones, Associate Professor of Pathology, Pathology
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Steinbach, William J., Professor of Pediatrics, Molecular Genetics and Microbiology
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Woodward, Julie Ann, Professor of Ophthalmology, Dermatology
  • Zafar, Syed Yousuf, Associate Professor of Medicine, Medicine, Medical Oncology